Filing Flows › West Pharmaceutical Services (WST) › R&D spending
West Pharmaceutical Services (WST) R&D spending by quarter
West Pharmaceutical Services' R&D spending was $19.7M in Q2 2026 (second quarter 2026), +25% from Q1 2026. Over the last 6 quarters it ranged from $15.8M (Q1 2026) to $21.8M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $19.7M | +25% | +3% |
| Q1 2026 | $15.8M | -28% | -3% |
| Q4 2025 | $21.8M | +27% | — |
| Q3 2025 | $17.1M | -10% | — |
| Q2 2025 | $19.1M | +17% | — |
| Q1 2025 | $16.3M | — | — |
Q2 2026 at a glance
West Pharmaceutical Services, Q2 2026: revenue $872M (+14% year over year), operating margin 20.5%, net earnings $154M, operating cash flow $124M. The chart follows the revenue to costs, profit and cash.
Questions
What is West Pharmaceutical Services' R&D spending?
West Pharmaceutical Services' R&D spending was $19.7M in Q2 2026 (second quarter 2026), +25% from Q1 2026.
How has West Pharmaceutical Services' R&D spending changed?
Over the last 6 quarters it ranged from $15.8M (Q1 2026) to $21.8M (Q4 2025).
Q2 2026 results → · How West Pharmaceutical Services makes money →